Nisa Investment Advisors
CTKB icon

Nisa Investment Advisors’s Cytek Biosciences CTKB Stock Holding History

Nisa Investment Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.4K Buy
3,754
+101
+3% +$477 ﹤0.01% 2084
2025
Q4 		$18.4K Sell
3,653
-1,227
-25% -$5.7K ﹤0.01% 1973
2025
Q3 		$16.9K Buy
4,880
+327
+7% +$1.23K ﹤0.01% 2070
2025
Q2 		$15.5K Buy
4,553
+2,993
+192% +$9.97K ﹤0.01% 2065
2025
Q1 		$6.26K Sell
1,560
-639
-29% -$3.31K ﹤0.01% 2199
2024
Q4 		$14.3K Buy
2,199
+183
+9% +$1.09K ﹤0.01% 2043
2024
Q3 		$11.2K Buy
2,016
+267
+15% +$1.51K ﹤0.01% 2079
2024
Q2 		$9.76K Buy
1,749
+334
+24% +$2.01K ﹤0.01% 2161
2024
Q1 		$9.49K Buy
1,415
+60
+4% +$475 ﹤0.01% 2047
2023
Q4 		$12.4K Sell
1,355
-6,505
-83% -$40.9K ﹤0.01% 1993
2023
Q3 		$43.4K Buy
7,860
+6,600
+524% +$52.9K ﹤0.01% 1766
2023
Q2 		$10.8K Sell
1,260
-830
-40% -$7.45K ﹤0.01% 2244
2023
Q1 		$19K Buy
2,090
+50
+2% +$538 ﹤0.01% 2022
2022
Q4 		$21K Sell
2,040
-41
-2% -$551 ﹤0.01% 2043
2022
Q3 		$32K Buy
2,081
+381
+22% +$4.95K ﹤0.01% 1903
2022
Q2 		$18K Buy
+1,700
New +$16.9K ﹤0.01% 2069

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nisa Investment Advisors's CTKB Position: Q1 2026 in Review

Nisa Investment Advisors increased its Cytek Biosciences (CTKB) stake by 2.8% in Q1 2026, buying an estimated $477 and bringing the position to 3,754 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Nisa Investment Advisors first reported a position in CTKB in Q2 2022 and has held it in 16 quarters since. The position peaked at $43.4K in Q3 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Nisa Investment Advisors held 3,754 shares of Cytek Biosciences worth $16.4K as of Q1 2026.
  • Nisa Investment Advisors bought 101 Cytek Biosciences shares in Q1 2026, an estimated $477.
  • Cytek Biosciences made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2084 holding.
  • Nisa Investment Advisors first reported a position in Cytek Biosciences in Q2 2022 and has held it in 16 quarters since.
  • Nisa Investment Advisors's Cytek Biosciences position peaked at $43.4K in Q3 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.